Last week, the Pharmaceutical Executive published its latest annual ranking of the top 50 biopharma companies
according to prescription drug sales in 2016. Once again, Pfizer
leads the ranking with $45,906 million in sales spurred by its top sellers Prevnar 13, Lyrica and Enbrel.
Despite being listed fourth in prescription sales, Merck & Co.
(not to be confused with the German-based Merck KGaA) spent the most on research and development compared to its competitors.
Here is our top ten in Big Pharma: